Quick Answer
CAPRICOR THERAPEUTICS, INC. reported Research And Development Expense of $84.45 million for the year ending 2025.
- CAPRICOR THERAPEUTICS, INC. showed an increase of +69.0% in Research And Development Expense from 2024 to 2025.
- This data is from CAPRICOR THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), CAPRICOR THERAPEUTICS, INC.'s Research And Development Expense has grown by 1,969.5%.
- Historical annual values: Fiscal year 2025: $84.45 million | Fiscal year 2024: $49.97 million | Fiscal year 2023: $36.45 million | Fiscal year 2022: $21.82 million | Fiscal year 2021: $13.57 million | Fiscal year 2020: $8.46 million | Fiscal year 2019: $5.14 million | Fiscal year 2018: $12.07 million | Fiscal year 2017: $10.77 million | Fiscal year 2016: $16.04 million | Fiscal year 2015: $13.76 million | Fiscal year 2014: $7.79 million | Fiscal year 2013: $5.20 million | Fiscal year 2012: $2.63 million | Fiscal year 2011: $4.14 million | Fiscal year 2010: $4.08 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: